Background: The best known hereditary colorectal cancer syndromes, familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC), constitute about 2% of all colorectal cancers, and there are at least as many non-FAP, non-HNPCC cases where the family history suggests a dominantly inherited colorectal cancer risk. Recently, a locus on chromosome 9q22.2–31.2 was identified by linkage analysis in sib pairs with colorectal cancer or adenoma.
Methods: Linkage analysis for the suggested locus on chromosome 9 was carried out in an extended Swedish family. This family had previously been investigated but following the identification of adenomas in several previously unaffected family members, these subjects were now considered to be gene carriers.
Results: In the present study, we found linkage of adenoma and colorectal cancer to chromosome 9q22.32–31.1 with a multipoint LOD score of 2.4. We were also able to define the region for this locus to 7.9 cM between the markers D9S280 and D9S277.
Conclusions: Our result supports the presence of a susceptibility locus predisposing to adenoma and colorectal cancer in this chromosomal region.
- FAP, familial adenomatous polyposis
- HNPCC, hereditary non-polyposis colorectal cancer
- LOD, logarithm of odds
- LOH, loss of heterozygosity
- MMR, mismatch repair
- chromosome 9
- colorectal cancer
- linkage analysis
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We thank the Swedish Cancer Foundation, the Swedish Cancer Society (03-0300, 3557), the Stockholm Cancer Society (03:316), the Nilsson-Ehle Foundation, the Academy of Finland, the Sigrid Juselius Foundation, the Finnish Cancer Foundation, the National Institutes of Health/National Cancer Institute (CA82282), and the Norwegian Cancer Society (A95068) for financial support.
Competing interests: none declared
Ethical approval: ethical approvals (no. D97205 and 2000-291) were received from the ethics committee at Karolinska Institute, Stockholm